Alpha-1 antitrypsin: A novel biomarker and potential therapeutic approach for metabolic diseases

It is well recognized that chronic low-grade systemic inflammation and autoimmunity contribute to the patho-genesis of metabolic syndrome, its associated diseases (e.g. type 2 diabetes, non-alcoholic fatty liver disease) and type 1 diabetes, respectively. Consequently, anti-inflammatory agents might play a role in managing these im-mune associated metabolic diseases. Alpha-1 antitrypsin (AAT), an endogenous acute phase protein being used for treatment of AAT deficiency (a rare genetic disease), has multiple functions including anti-inflammatory, immunomodulatory, anti-apoptosis and cytoprotective effects. In this review, we summarized basic and clin-ical studies that reported potential therapeutic role of AAT in metabolic syndrome associated diseases and type 1 diabetes. Studies that demonstrated AAT had the possibility to be used as a novel biomarker to predict these immune associated metabolic diseases were also included.

Automated summary

This review summarizes the potential therapeutic role of AAT in metabolic syndrome associated diseases and type 1 diabetes, as well as studies demonstrating its potential use as a novel biomarker.